Cannabinoids have been shown to promote the expression of the
intercellular adhesion molecule 1 (ICAM-1) on
lung cancer cells as part of their anti-invasive and antimetastatic action. Using
lung cancer cell lines (A549, H460) and metastatic cells derived from a
lung cancer patient, the present study addressed the impact of
cannabinoid-induced
ICAM-1 on
cancer cell adhesion to lymphokine-activated killer (LAK) cells and LAK cell-mediated cytotoxicity.
Cannabidiol (CBD), a non-psychoactive
cannabinoid, enhanced the susceptibility of
cancer cells to adhere to and subsequently be lysed by LAK cells, with both effects being reversed by a neutralizing
ICAM-1 antibody. Increased
cancer cell lysis by CBD was likewise abrogated when CBD-induced
ICAM-1 expression was blocked by specific
siRNA or by antagonists to
cannabinoid receptors (CB1, CB2) and to transient receptor potential vanilloid 1. In addition, enhanced killing of CBD-treated
cancer cells was reversed by preincubation of LAK cells with an antibody to
lymphocyte function associated antigen-1 (LFA-1) suggesting intercellular ICAM-1/LFA-1 crosslink as crucial event within this process. ICAM-1-dependent pro-killing effects were further confirmed for the phytocannabinoid Δ(9)-tetrahydrocannabinol (
THC) and
R(+)-methanandamide (MA), a hydrolysis-stable
endocannabinoid analogue. Finally, each
cannabinoid elicited no significant increase of LAK cell-mediated lysis of non-
tumor bronchial epithelial cells, BEAS-2B, associated with a far less pronounced (CBD,
THC) or absent (MA)
ICAM-1 induction as compared to
cancer cells. Altogether, our data demonstrate
cannabinoid-induced upregulation of
ICAM-1 on
lung cancer cells to be responsible for increased
cancer cell lysis by LAK cells. These findings provide proof for a novel antitumorigenic mechanism of
cannabinoids.